Rosemary Habib1,2,3,4, Nicholas G Burgess3,5, Michael J Bourke3,5, Mark Wong2,3,6, Nicholas Wilcken2,3, James Toh3,7, Toufic El-Khoury3,7,8, Nimalan Pathma-Nathan7, Grahame Ctercteko7, Jayasingham Jayamohan3,9, Kenneth Micklethwaite1,3,4,10, Adnan Nagrial2,3,6. 1. Westmead Clinical School, The University of Sydney, Sydney, Australia. 2. Department of Medical Oncology, Westmead Hospital, Crown Princess Mary Cancer Centre, Sydney, New South Wales, Australia. 3. Westmead Clinical School, The University of Sydney, Sydney, New South Wales, Australia. 4. The Westmead Institute for Medical Research, Westmead, New South Wales, Australia. 5. Department of Gastroenterology and Hepatology, Westmead Hospital, Sydney, New South Wales, Australia. 6. Blacktown hospital, Blacktown Cancer and Haematology Centre, Sydney, New South Wales, Australia. 7. Division of Colorectal Surgery, Department of Surgery, Westmead Hospital, Sydney, New South Wales, Australia. 8. University of Notre Dame, Sydney, New South Wales, Australia. 9. Department of Radiation Oncology, Westmead Hospital, Crown Princess Mary Cancer Centre, Sydney, New South Wales, Australia. 10. Sydney Cellular Therapies Laboratory, Blood and Bone Marrow Transplant Unit, Department of Haematology, Westmead Hospital, Sydney, NSW, Australia.
Abstract
BACKGROUND: The incidence of rectal cancer is higher in the older population. In developed nations, there has been a rise in incidence in young onset colorectal cancer (CRC). We examined the outcomes of locally advanced rectal cancer (LARC) in younger patients (yRC) compared with older patients, using a retrospective audit. METHODS: All cases of LARC referred to two tertiary referral cancer centres in Western Sydney were examined. Patient demographics, presenting symptoms, treatment, relapse free survival (RFS), overall survival (OS) and progression free survival (PFS) were obtained. Under 50 years old was used as the cut-off age for defining yRC. RESULTS: All 145 consecutive patients were treated for LARC, including 28 in the yRC and 117 in the older patient group. Median follow-up was 54 months. yRC were more likely to complete neoadjuvant therapy (100% vs. 86%; P=0.032) and to undergo more extensive surgical procedures (24% vs. 2%, P<0.0001). yRC were more likely to have microsatellite high (MSI) tumours (30% vs. 4.7%; P=0.003). yRC demonstrated significantly poorer RFS compared with the standard group (HR 2.79; median RFS 4.67 vs. 16.02 months; P=0.023). In the relapsed setting, yRC had poorer PFS compared with the standard group (median PFS 2.66 vs. 9.70, P=0.006, HR 3.04). A difference in OS was also seen between the two groups, with yRC demonstrating poorer OS (median OS 40.46 vs. 58.26 months, HR 3.48, P=0.036). CONCLUSIONS: Patients under 50 years with LARC are more likely to have MSI tumours with a more aggressive disease course and poorer RFS, PFS and OS. Initiatives to improve early detection of these patients may improve outcomes. Further research is necessary to understand this disease and optimise its treatment. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
BACKGROUND: The incidence of rectal cancer is higher in the older population. In developed nations, there has been a rise in incidence in young onset colorectal cancer (CRC). We examined the outcomes of locally advanced rectal cancer (LARC) in younger patients (yRC) compared with older patients, using a retrospective audit. METHODS: All cases of LARC referred to two tertiary referral cancer centres in Western Sydney were examined. Patient demographics, presenting symptoms, treatment, relapse free survival (RFS), overall survival (OS) and progression free survival (PFS) were obtained. Under 50 years old was used as the cut-off age for defining yRC. RESULTS: All 145 consecutive patients were treated for LARC, including 28 in the yRC and 117 in the older patient group. Median follow-up was 54 months. yRC were more likely to complete neoadjuvant therapy (100% vs. 86%; P=0.032) and to undergo more extensive surgical procedures (24% vs. 2%, P<0.0001). yRC were more likely to have microsatellite high (MSI) tumours (30% vs. 4.7%; P=0.003). yRC demonstrated significantly poorer RFS compared with the standard group (HR 2.79; median RFS 4.67 vs. 16.02 months; P=0.023). In the relapsed setting, yRC had poorer PFS compared with the standard group (median PFS 2.66 vs. 9.70, P=0.006, HR 3.04). A difference in OS was also seen between the two groups, with yRC demonstrating poorer OS (median OS 40.46 vs. 58.26 months, HR 3.48, P=0.036). CONCLUSIONS: Patients under 50 years with LARC are more likely to have MSI tumours with a more aggressive disease course and poorer RFS, PFS and OS. Initiatives to improve early detection of these patients may improve outcomes. Further research is necessary to understand this disease and optimise its treatment. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
Authors: Eleonora Feletto; Xue Qin Yu; Jie-Bin Lew; D James B St John; Mark A Jenkins; Finlay A Macrae; Suzanne E Mahady; Karen Canfell Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-12-07 Impact factor: 4.254
Authors: Aaron J Franke; Hiral Parekh; Jason S Starr; Sanda A Tan; Atif Iqbal; Thomas J George Journal: Clin Colorectal Cancer Date: 2017-06-27 Impact factor: 4.481
Authors: Jessica B O'Connell; Melinda A Maggard; Jerome H Liu; David A Etzioni; Clifford Y Ko Journal: Dis Colon Rectum Date: 2004-12 Impact factor: 4.585
Authors: K K Chan; B Dassanayake; R Deen; R E Wickramarachchi; S K Kumarage; S Samita; K I Deen Journal: World J Surg Oncol Date: 2010-09-15 Impact factor: 2.754
Authors: Simon J Dovedi; Amy L Adlard; Grazyna Lipowska-Bhalla; Conor McKenna; Sherrie Jones; Eleanor J Cheadle; Ian J Stratford; Edmund Poon; Michelle Morrow; Ross Stewart; Hazel Jones; Robert W Wilkinson; Jamie Honeychurch; Tim M Illidge Journal: Cancer Res Date: 2014-10-01 Impact factor: 12.701
Authors: Ulrich Nitsche; Anina Zimmermann; Christoph Späth; Tara Müller; Matthias Maak; Tibor Schuster; Julia Slotta-Huspenina; Samuel A Käser; Christoph W Michalski; Klaus-Peter Janssen; Helmut Friess; Robert Rosenberg; Franz G Bader Journal: Ann Surg Date: 2013-11 Impact factor: 12.969
Authors: Justin Guinney; Rodrigo Dienstmann; Xin Wang; Aurélien de Reyniès; Andreas Schlicker; Charlotte Soneson; Laetitia Marisa; Paul Roepman; Gift Nyamundanda; Paolo Angelino; Brian M Bot; Jeffrey S Morris; Iris M Simon; Sarah Gerster; Evelyn Fessler; Felipe De Sousa E Melo; Edoardo Missiaglia; Hena Ramay; David Barras; Krisztian Homicsko; Dipen Maru; Ganiraju C Manyam; Bradley Broom; Valerie Boige; Beatriz Perez-Villamil; Ted Laderas; Ramon Salazar; Joe W Gray; Douglas Hanahan; Josep Tabernero; Rene Bernards; Stephen H Friend; Pierre Laurent-Puig; Jan Paul Medema; Anguraj Sadanandam; Lodewyk Wessels; Mauro Delorenzi; Scott Kopetz; Louis Vermeulen; Sabine Tejpar Journal: Nat Med Date: 2015-10-12 Impact factor: 53.440